We have investigated copy number variations (CNVs) in relation to cervical cancer by analyzing 731,422 single-nucleotide polymorphisms (SNPs) in 1,034 cervical cancer cases and 3,948 controls, followed by replication in 1,396 cases and 1,057 controls.
Abstract
We have investigated copy number variations (CNVs) in relation to cervical cancer by analyzing 731,422 single-nucleotide polymorphisms (SNPs) in 1,034 cervical cancer cases and 3,948 controls, followed by replication in 1,396 cases and 1,057 controls.
We found that a 6367bp deletion in intron 1 of the CTD small phosphatase like gene (CTDSPL) was associated with 2.54-fold increased risk of cervical cancer (odds ratio =2.54, 95% confidence interval =2. 08-3.12, P=2.0×10 -19 ). This CNV is one of the strongest genetic risk variants identified so far for cervical cancer. 
Introduction
Cervical cancer is the third most common cancer in women worldwide (Arbyn et al. 2011 ). Genome-wide association studies (GWASs) focusing on single-nucleotide polymorphisms (SNPs) have identified multiple genetic susceptibility loci for cervical cancer (Chen et al. 2013; Shi et al. 2013 ). However, the risk variants identified to date have small effect sizes (per allele odds ratio (OR) < 1.50) and only explain a small fraction of the heritability. Although epistatic and gene-environment interactions may contribute to the unexplained heritability of cervical cancer, it seems likely that a significant fraction is due to loci that have not yet been identified. Recent studies indicate that copy number variations (CNVs) occur frequently in the genome and are an important source of human genetic variation (Iafrate et al. 2004; Sebat et al. 2004 ).
It has been proposed that CNVs may explain some of the missing heritability for complex diseases after the findings from GWASs (Eichler et al. 2010 ).
The role of somatic CNVs in cervical cancer has been extensively studied (Snijders et al. 1998; Ng et al. 2007; Mitra et al. 2010a; Lee et al. 2012; Mendoza-Rodriguez et al. 2013; Lee et al. 2014; Zhou et al. 2017 ). However, very few studies have evaluated the association of germline CNVs with cervical cancer risk.
Only one study demonstrated that a lower defensin beta 104A (DEFB4) copy number was associated with susceptibility to cervical cancer (Abe et al. 2013) . To assess the association of both common and rare germline CNVs with cervical cancer risk, we conducted a genome-wide CNV study of 1,034 cervical cases and 3,948 controls in a Swedish population using Illumina HumanOmniExpress BeadChip (Illumina, San change: 1.18, 1.16, 1.19, 1.09 respectively, all P< 0.05, Table 1 ). The difference between patients and controls was particularly strong for duplications (fold change:
1.24, 1.22, 1.25, 1.19 for all duplications, all genic duplications, rare duplications and rare genic duplications respectively, all with a P<0.05, Table 1 ). All analyses, except for rare genic deletions (fold change=1.05, P = 0.13), reached statistical significance (P < 0.05).
We then explored whether individual genes impacted by deletions or duplications were associated with susceptibility to cervical cancer. The strongest association was found for a 6367bp deletion in intron 1 of the CTD small phosphatase like gene (CTDSPL) (chr3: 37979882-37986249), which was found in 7.4 % of cervical cancer cases and 2.6 % of controls (odds ratio (OR)=2.61, 95% confidence interval (CI)=1. 91-3.56, P=1.5×10 -9 , BFDP <0.5 when the prior probability is 0.5 or 0.05) ( ) also reached statistical significance but failed correction for multiple testing when the prior probability is 0.05 and 0.5, respectively ( Table 2) . To verify the accuracy of CNV calls, we reanalyzed a proportion of samples using both real-time quantitative PCR (RT-qPCR) and Custom Taqman Copy Number Assays (Life Technologies). Deletion of ATP13A4 was excluded from further investigation as it was unable to be designed for RT-qPCR or Taqman assay. Both the SybrGreen RT-qPCR and Custom Taqman
Assays showed 100% concordance with the CNV calls from GWAS data on 99 cervical cancer cases tested for CTDSPL and 75 cervical cancer cases tested for NEDD4L based on the SNP arrays.
The association with deletion in CTDSPL was further replicated in an independent study of 1,396 cervical cancer subjects and 1,057 controls (OR=1.31, 95%CI=1.05-1.65, P=0.017) from the Swedish population (Methods, Table 3 ). The frequency of the deletion is 0.17 and 0.14 in the cancer patients and controls, respectively. In contrast, no association was observed between deletion in NEDD4L and cervical cancer risk in the replication series (OR=1.04, 95% CI=0.48-2.26,
P=0.92).
Using the combined discovery and replication data, the deletion in CTDSPL showed an OR = 2.54 (95% CI = 2.08-3.12, P = 2.0×10 -19 ) with risk of cervical cancer. No heterogeneity for the association of CTDSPL deletion with cervical cancer risk was noted by tumour stage (CIS vs invasive cancer) (P = 0.12).
The effect of CTDSPL deletion on transcription
RNA-seq data in cervical cancer tissues from 293 individuals in The Cancer Genome Atlas (TCGA) (http://www.cancergenome.nih.gov) indicated that the 6367bp deletion was significantly associated with decreased expression of CTDSPL (Spearman coefficient = 0.54, P = 1.4×10 -23 ), supporting that the deletion affects the transcription of CTDSPL (Methods). There are 3 other genes (villin like (VILL), phospholipase C delta 1(PLCD1) and deleted in lung and esophageal cancer 1 (DLEC1)) within the 200kb range of the deletion. We analyzed the data from TCGA to examine the association between the CTDSPL CNV and the expression level of these candidate genes (Methods). One-way ANOVA results suggested that expression level of CTDSPL showed more significant association with CNV of CTDSPL than the other genes (7.3×10 -19 vs 0.02, 0.001 and 0.75, respectively) (Figure 2 , Table 4 ). In addition, the significance of the correlation with VILL and PLCD1 did not remain in the linear regression analysis, while CTDSPL itself still showed remarkable significance (5.1×10
-9
, Table 5 ). Therefore, we speculated that the deletion of CTDSPL may be more likely to affect the transcription of CTDSPL itself rather than the surrounding genes. U  S  F  2  )  (  c  h  r  3  :  3  7  ,  9  8  1  ,  9  8  5  -3  7  ,  9  8  2  ,  2  4  8  )  ,   a  c  t  i  v  a  t  i  n  g  t  r  a  n  s  c  r  i  p  t  i  o  n  f  a  c  t  o  r  3  (  A  T  F  3  )  c  h  r  3  :  3  7  ,  9  8  2  ,  0  5  8  -3  7  ,  9  8  2  ,  2  9 The effect of the location of this fragment on transcriptional regulation was examined by luciferase reporter assays using two constructs containing the fragment upstream and downstream of the SV40 promoter, respectively (Methods, Figure 4A ).
Relative promoter activity was determined in HEK293T cells that over and under-express ZNF263, respectively. Both constructs containing the CTDSPL-6367bp fragment upstream or downstream of the SV40 promotor generated higher luciferase signals as compared to PGL3-Controls without the CTDSPL-6367bp fragment, when transfecting 293T which overexpressed ZNF263 through lentiviral plasmid construction (P = 0.04, P = 0.03, respectively) ( Figure 4B ), suggesting that the location of the CTDSPL-6367bp fragment relative to the SV40 promoter (upstream or downstream) did not affect the transcriptional activity. However, there was no significant difference in the luciferase signal between constructs containing the fragment and PGL3-Control when transfecting 293T that did not overexpress ZNF263
(P > 0.05) ( Figure 4C ). Then we examined relative promoter activity using construct containing the fragment upstream of the SV40 promoter in HEK293T cells that overexpress ZNF263, 
Function of CTDSPL in cervical cancer
To determine the function of CTDSPL in human cervical cancers, we ectopically expression in luciferase-expressing End1/E6E7 cells ( Figure 6G ). We then examined the effect of CTDSPL depletion on tumourigenicity by subcutaneous injection into mice with End1/E6E7 cells transduced with shCtrl or shCTDSPL (Methods). We observed that the mice implanted with control cells were viable and did not develop tumours when sacrificed, whereas CTDSPL-depleted immortalized End1/E6E7 could form tumours in NOD-SCID mice ( Figure 6H ). The tumor burden in the whole cohort was shown in Figure 3I .
Discussion
We have performed the first genome-wide CNV study of cervical cancer. We found that a 6367bp deletion in intron 1 of CTDSPL was associated with 2.54-fold increased CTDSPL encodes a protein phosphatase that dephosphorylates RB1, halting the cell cycle at the G1/S boundary, thereby controlling cell proliferation (Luo et al. 2015) . It is conserved from yeast to human. CTDSPL is frequently deleted in cervical tumour and cervical intraepithelial neoplasia (CIN). The deletions in CTDSPL have been found to be significantly higher in squamous cell carcinoma (SCC) with metastases than in SCC without metastases, and decreased expression was more frequent in SCC with metastases as compared to SCC without metastases (Kashuba et al. 2009 ). Reduced expression of CTDSPL in SiHa and CaSki along with tumour suppressive ability has been reported in both in vitro and in vivo systems (Anedchenko et al. 2007 ). The promoter of CTDSPL is highly methylated in cervical cancer (Mitra et al. 2010b ). Furthermore, CTDSPL deletion is associated with poor prognosis of cervical cancer patients (Mitra et al. 2010b) . Therefore, we could only oversample subjects with the deletion and randomly selected subjects without the deletion for technical validation. Second, there are no SNPs on the Illumina HumanOmniExpress BeadChip that cover DEFB4 in our study.
Therefore, we could not evaluate the association between DEFB4 copy number and susceptibility to cervical cancer.
In summary, we found that a 6367bp deletion in intron 1 of CTDSPL was associated with 2.54-fold increased risk of cervical cancer. This CNV is one of the strongest genetic risk variants identified so far for cervical cancer. This deletion removes the binding sites of ZNF263, GATA2 and IRF1, and hence downregulates the transcription of CTDSPL. In vitro and in vivo studies suggest that CTDSPL is a tumour suppressor gene for cervical cancer.
Methods

Study population
Subjects included in the discovery phase were from a GWAS of cervical cancer in the Swedish population. The details of population and quality controls have been described elsewhere (Chen et al. 2013) . Briefly, subjects included in the discovery phase were from two studies, the CervixCan I study and the TwinGene study.
CervixCan study included two parts, i.e. CervixCan Ι study that comprised cases who are the sole participants of their family and CervixCan II study that comprised individuals with more than one first-degree relative also participating. 766 sole participants (720 CIS and 46 invasive carcinoma) from the CervixCan Ι study were included in the discovery phase. The TwinGene study was a population-based Swedish study of twins born between 1911 and 1958. In total, 9,896 subjects were genotyped consecutively with those from the CervixCan Ι study using Illumina
HumanOmniExpress BeadChip (731,422 SNPs) at the SNP&SEQ Technology Platform Uppsala, Sweden. Among these subjects, 309 unrelated cervical cancer cases (288 CIS and 21 invasive carcinoma) were further included in the discovery phase.
One female singleton was then randomly selected from each twin pair without cervical cancer, resulting in 4,014 unrelated cervical cancer-free females who were included as controls. After stringent quality control (Chen et al. 2013 from CervixCan II study and 1,057 controls. All the subjects were of Swedish descent.
Informed consent was obtained from all subjects and each study was approved by the regional ethical review board in Uppsala, Sweden.
CNV detection
CNV coordinates were identified using both Penncnv and Quantisnp (Colella et al.
2007; Wang et al. 2007). Both of the two algorithms are based on a Hidden Markov
Model (HMM), using intensity files generated by GenomeStudio software from Illumina. QuantiSNP2.0 is based on an objective Bayes HMM and takes into consideration log R Ratio (LRR) as well as B allele frequency (BAF) of each SNP.
The PennCNV algorithm incorporates additional information including the population frequency of the B allele (PFB) and the distance between adjacent SNPs. To reduce false positive calls due to genomic waves, GC-content adjustment was performed to correct for the bias in both analyses (Diskin et al. 2008 ). The default setting was used for both algorithms.
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genome. CNVs with a frequency ≤ 1.0% in our dataset were defined as rare CNVs.
Genic CNVs were defined as CNVs overlapped with one or more genes (Genes were determined by RefSeq annotations (UCSC, Feb 2009, GRCh37/hg19) and gene boundaries were extended with a 10 kb flanking region on either side (Pinto et al.
2010)
). We first evaluated the burden of deletions and duplications together, followed by one or the other separately. Significant differences were determined by 1 × 10 6 permutations via PLINK (Purcell et al. 2007 ).
Gene-based analysis
The numbers of patients and controls in whom a given gene was affected by CNVs were counted and compared. Permutation tests (1 × 10 6 iterations) were carried out for individual genes by PLINK and permutation correction for multiple testing for all genes was performed with the max (T) permutation (mperm) option of PLINK (Purcell et al. 2007 ). In addition, odds ratio (OR), 95 % confidence interval (CI) and P values for specific CNV-disrupted genes for the risk of cervical cancer were calculated by logistic regression in the allelic test using the SAS 9.3 software. Bayes false discovery probability (BFDP) calculation was performed to reduce the probability of false-positive findings from GWAS stage. Two levels of prior probability (0.05 and 0.005) was selected and prior OR of 1.5 was adopted, which was suggested by Wachoder et al for a detrimental variant. BFDP <0.5 was used to indicate noteworthy findings (Wakefield 2007) .
Technical Replication
CNVs in CTDSPL and NEDD4L were technically validated using SybrGreen Samples were denatured at 95°C for 10 min followed by 40 cycles of 15 sec denaturation at 95°C and 1 min annealing at 60°C.
Independent Replication
CTDSPL and NEDD4L CNVs were independently determined in the replication cohort by using Custom Taqman Copy Number Assays (Life Technologies). 
Replication and combined statistical analysis
To account for the correlation between related subjects in the replication and combined datasets, the association analysis was performed using PedGenie that keratinocyte growth supplement, 100 U/ml penicillin and 100 mg/ml streptomycin.
All cells were maintained at 37℃ in a 5% CO 2 incubator.
Lentiviral plasmid construction, lentiviral production and over-expression of
ZNF263 cell line screening
The gene ZNF263 was PCR-amplified from a human cDNA library and was fused into a lentiviral vector containing an EF1α promoter, which co-expressed an EGFP fluorescence protein from a CMV promoter. The lentiviruses of ZNF263 were obtained by co-transfection with three viral packaging plasmids pLP1, pLP 2 and pLP VSV-G into HEK293T using CaCl2 transfection. Virus was harvested 48 hr post-transfection. For viral transduction, cells were incubated with culture-medium-diluted viral supernatant for 24 hr. At 72 hr following transduction, the EGFP-positive population was reached to more than 90 %.
Plasmid construction and luciferase assays in HEK293T stably overexpressing
ZNF263
The CTDSPL intron 1-6367 bp fragment was PCR-amplified from 293T genomic DNA. To explore directionality of the regulatory element, we cloned the fragment upstream and downstream of SV40 of the pGL3-promoter vector (Promega), respectively. Inserts in each construct were verified by sequencing. Primer sequences are available on request. Constructs were transfected with equimolar amounts (800 ng) for luciferase reporter plasmids into HEK293T and HEK293-ZNF263 using lipofectamine 2000 reagent (Invitrogen), according to manufacturer's instructions. Cells were harvested after 48h. Luminescence activity
was measured with a Berthold lumat LB9507. Assays were performed in triplicate wells. Data represent at least three independent experiments. Statistical significance between experimental groups was assessed using a T test analysis. All analyses were performed using SAS 9.3, and a two tailed P value <0.05 was considered significant.
Plasmid construction and luciferase assays in HEK293T stably overexpressing
ZNF263
The CTDSPL intron 1-6367 bp fragment was PCR-amplified from HEK293T genomic DNA. To explore directionality of the regulatory element, we cloned the fragment upstream and downstream of SV40 of the pGL3-promoter vector (Promega), respectively. Inserts in each construct were verified by sequencing. Primer sequences are available on request. Constructs were transfected with equimolar amounts (800 ng) for luciferase reporter plasmids into HEK293T and HEK293-ZNF263 using lipofectamine 2000 reagent (Invitrogen), according to manufacturer's instructions. Cells were harvested after 48h. Luminescence activity was measured with a Berthold lumat LB9507. Assays were performed in triplicate wells. Data represent at least three independent experiments. Statistical significance between experimental groups was assessed using a T test analysis. All analyses were performed using SAS 9.3, and a two tailed P value <0.05 was considered significant.
Plasmid construction and luciferase assays in HEK293T transiently
overexpressing FMO3, Statistical significance between experimental groups was assessed using T test. All analyses were performed using SAS 9.3, and a two tailed P value <0.05 was considered significant. 
Plasmid construction and colony formation assay
Immunohistochemistry
The immunohistochemistry assay was conducted on nude mouse xenograft tumour tissues to detect and score CTDSPL and Ki-67 expression using methods described previously (Luo et al. 2015) . CTDSPL and Ki-67 antibodies was obtained from Novus Biologicals. Statistical significance between experimental groups was assessed using a T-test. All analyses were performed using SAS 9.3, and a two tailed P value < 0.05 was considered significant.
Tumour xenograft models
All animal experiments were conducted with the approval of the Shanghai Jiao Tong University Institutional Committee for Animal Research and in conformity with national guidelines for the care and use of laboratory animals. Cells infected with a luciferase-encoding lentivirus (1 × 10 6 ) were inoculated subcutaneously into nude mice. There were 8 mice in each experimental group. Tumour volume (V) was monitored by measuring tumour length (L) and width (W) with callipers and then calculated with the formula (L×W2) × 0.5. Statistical significance between experimental groups was assessed using a T-test. All analyses were performed using SAS 9.3, and a two tailed P value <0.05 was considered significant. 
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